KYTX — Kyverna Therapeutics Share News
0.000.00%
Last trade - 00:00- $354.36m
- $179.94m
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden Restaurants
Kyverna rises as cell therapy shows durable benefit in rare nerve disease
Brief: Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses And Favorable Safety Profile For Miv-Cel In Stiff Person Syndrome And Generalized Myasthenia Gravis
Kyverna Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a share - Earnings Preview
Brief: Kyverna Therapeutics And Elevatebio Enter Into Commercial Manufacturing And Supply Agreement For Miv-Cel
Biotech experts want FDA drug reviews based on science, not politics (updated)
Biotech experts want FDA drug reviews based on science, not politics
Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant options
Brief: Kyverna Therapeutics Names Greg Martini As Chief Financial Officer
Brief: Kyverna Therapeutics Reports First Quarter 2026 Financial Results
Brief: Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader In Neurology And Rare Disease, As Chief Commercial Officer
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway
U.S. STOCKS ON THE MOVE-Certara, Otis, Twilio
U.S. STOCKS ON THE MOVE-Best Buy, Teleflex, Philip Morris
U.S. STOCKS ON THE MOVE-Adobe, GE Vernova, Calix